Alexion guides cautiously for 2018

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) reported strong 4Q17 earns Thursday, including sales of hematology and autoimmune drug Soliris eculizumab, but its 2018 guidance fell shy of the Street’s expectations.

Alexion reported 4Q17 non-GAAP EPS of $1.48 on revenues of $910 million, beating consensus EPS of $1.27 and revenues of $880 million...